免疫检查点抑制剂疗效预测标记物  

Predictive biomarkers for checkpoint blockade-based immunotherapy

作　　者：游路宽 胡毅[1] 

机构地区：[1]解放军总医院肿瘤内科,北京100853

出　　处：《解放军医学院学报》2018年第2期161-164,共4页Academic Journal of Chinese PLA Medical School

基　　金：国家自然科学基金项目(81672996)~~

摘　　要：近年来,免疫治疗开创了肿瘤治疗的新时代,特别是免疫检查点抑制剂取得不少令人振奋的进展。有效预测免疫检查点抑制剂疗效,对于改善肿瘤患者临床获益显得越发必要。本文对目前临床常用或具有极大临床应用潜能的疗效预测标记分子如肿瘤组织PD-L1表达、微卫星不稳定、突变负荷等进行综述。Recently, immunotherapy has ushered in an exciting era of anticancer therapy. The immune checkpoint blockades have made many encouraging advances in particular. To predict the efficacy of immune checkpoint blockades therapy for improving the clinical outcomes of cancer patients seems extraordinarily important. In this review, we describe the biomarkers which have been applied to clinical practice or have great potential for application, such as tumor tissue PD-L1 expression, microsatellite instability, mutation load and tumor infiltrating lymphocytes.

关 键 词：免疫检查点抑制剂 细胞程序死亡蛋白-配体1 微卫星不稳定 

分 类 号：R730.51[医药卫生—肿瘤]